Programmed death ligand-1 expression in non-small cell lung cancer
By V. Velcheti, K. Schalper, Daniel Carvajal, David L. Rimm, Valsamo Anagnostou, K. Syrigos, M. Sznol, R. Herbst, S. Gettinger, Lieping Chen. Laboratory Investigation, 2013
753 citations recorded by the source corpus.
Recent strategies targeting the interaction of the programmed cell death ligand-1 (PD-L1, B7-H1, CD274) with its receptor, PD-1, resulted in promising activity in early phase clinical trials. In this study, we used various antibodies and in situ mRNA hybridization to measure PD-L1 in non-small cell lung cancer (NSCLC) using a quantitative fluorescence (QIF) approach to determine the frequency of expression and prognostic value in two independent populations. A control tissue microarray (TMA) was constructed using PD-L1-transfected cells, normal human placenta and known PD-L1-positive NSCLC cases. Only one of four antibodies against PD-L1 (5H1) validated for specificity on this TMA. In situ PD-L1 mRNA using the RNAscope method was similarly validated. Two cohorts of NSCLC cases in TMAs including 340 cases from hospitals in Greece and 204 cases from Yale University were assessed. Tumors showed PD-L1 protein expression in 36% (Greek) and 25% (Yale) of the cases. PD-L1 expression was significantly associated with tumor-infiltrating lymphocytes in both cohorts. Patients with PD-L1 (both protein and mRNA) expression above the detection threshold showed statistically significant better outcome in both series (log-rank P=0.036 and P=0.027). Multivariate analysis showed that PD-L1 expression was significantly associated with better outcome independent of histology. Measurement of PD-L1 requires specific conditions and some commercial antibodies show lack of specificity. Expression of PD-L1 protein or mRNA is associated with better outcome. Further studies are required to determine the value of this marker in prognosis and prediction of response to treatments targeting this pathway.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/4755975a2a88418f9603531623e83335f3890c2e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer. (2016, background): “Indeed, receptor tyrosine kinase inhibitors resulted in better treatment outcome in lung cancers with high-expression of PD-L1 [93, 94].”
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (2015, neutral): “Febrile neutropenia 0 0 14 (11) 13 (10)”
- Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. (2015, neutral): “org Volume 125 Number 9 September 2015 small fraction of human cancers that lack TILs in the tumor microenvironment but still express high levels of PD-L1 (34, 36).”
- PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations (2016, background): “However, lymphocyte-rich regions may not always be associated with PD-L1 expression (41,78,102).”
- Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. (2016, background): “22 consistent in two separate TMA cohorts and suggests that PD-L1 is regulated at both transcription and translational levels (34).”
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation (2015, result): “Whereas, recently, some studies found PD-L1 was a positive prognostic factor in some solid tumors.(32,33) Recently, D’Incecco et al.”
- Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity (2016, positive): “Promising clinical outcomes in trials testing antibody blockade of the PD-1/PD-L1 pathway in melanoma 4 , lung cancer 5 and kidney cancer 6 have resulted in new treatment options for a broad spectrum of malignant cancers 7 .”
- Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy (2014, result): “This is consistent with retrospective studies in select tumor types, such as melanoma, Merkel cell carcinoma, mismatch repair–proficient colorectal cancer, and NSCLC where tumor PD-L1 expression has been shown to be a positive prognostic factor (12, 13, 27, 28).”
- PD-L1 expression in human cancers and its association with clinical outcomes (2016, neutral): “…not a significant negative factor of OS Patients with PD-L1 expression above the detection threshold showed statistically significant better outcome velcheti et al 27 The degree of T lymphocytes infiltration was slightly higher in PD-L1-positive tumors than in PD-L1-negative ones Higher PD-L1…”